Alexion Pharmaceuticals Inc. (ALXN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Alexion Pharmaceuticals ( ALXN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.7%. By the end of trading, Alexion Pharmaceuticals rose $1.07 (1.3%) to $84.46 on heavy volume. Throughout the day, four million shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock ranged in a price between $83.30-$85.28 after having opened the day at $84.44 as compared to the previous trading day's close of $83.39. Other companies within the Drugs industry that increased today were: Chelsea Therapeutics International ( CHTP), up 153.9%, Novogen ( NVGN), up 26%, Cornerstone Therapeutics ( CRTX), up 24.6%, and Cormedix ( CRMD), up 12.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Alexion Pharmaceuticals has a market cap of $16.71 billion and is part of the health care sector. The company has a P/E ratio of 40.4, above the S&P 500 P/E ratio of 17.7. Shares are down 8.2% year to date as of the close of trading on Tuesday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Oncolytics Biotech ( ONCY), down 16.5%, Aoxing Pharmaceutical Company ( AXN), down 14.6%, Oramed Pharmaceuticals ( ORMP), down 12.5%, and Bacterin International Holdings ( BONE), down 11.6%, were all laggards within the drugs industry with Valeant Pharmaceuticals International ( VRX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk